OSW-1
(Synonyms: Orsaponin) 目录号 : GC46194
OSW-1是从虎眼万年青中分离出来的,osterol-bindingprotein(OSBP)和OSBP-elated protein4(ORP4)的特异性拮抗剂。
Cas No.:145075-81-6
Sample solution is provided at 25 µL, 10mM.
OSW-1(Orsaponin) is a saponin found in Heterosmilax yunnanensis, inhibits oxysterol-binding protein (OSBP) and its paralog OSBP-related protein 4 (ORP4), and shows antiviral and anticancer activities[1]. OSW-1(Orsaponin) has been shown to repress cancer progression through inhibiting cell proliferation, arresting cell cycle, inducing apoptosis and Golgi stress response, as well as suppressing migration, invasion and angiogenesis by regulating miRNAs expression and various signaling pathways[2].
In vitro, OSW-1(Orsaponin) induced more apoptotic cells (MDA-MB-231 vs MDA-MB-453 cells, 52.5% vs 60.5%) than control groups after incubation with 100 ng/mL OSW-1 for 24 hours. Apoptosis ratio in OSW-1(Orsaponin) treatment groups was significantly elevated compared with control groups. OSW-1(Orsaponin) groups showed more apoptotic cells than control groups both in MDA-MB-231 and MDA-MB-453 cells. Compared with non- OSW-1(Orsaponin)-treated controls, both cleaved PARP and cleaved caspase 3 expressions in protein levels were increased in OSW-1(Orsaponin)-treated groups. Furthermore, the overexpressed cleaved poly ADP-ribose polymerase (PARP) and cleaved caspase 3 were found in 100 ng/mL OSW-1(Orsaponin)-treated cells than those in 50 ng/mL OSW-1-treated cells[3].
In vivo, OSW-1(Orsaponin) was injected intraperitoneally (0.01 mg/kg diluted in PBS in 500 µl, daily) in treated group when heterotopic xenograft tumor model in nude mouse subcutaneously inoculated by LoVo cells. Compared with the control group, the treated group observed a decrease in tumor size and weight without significant side effects, with fewer Ki-67-positive cells and more apoptotic cells[4]. OSW-1(Orsaponin)-treated tumor tissues had countless apoptotic cells, but few apoptotic cells in the control group, suggesting that OSW-1 suppressed colon tumor proliferation through apoptosis in vivo. A number of necrotic foci within the tumor tissues of control mice, but not in OSW-1(Orsaponin) mice, suggesting that tumor growth speed may be greater in control mice than OSW-1(Orsaponin)-treated mice[5].
Fig 1 Overview of the anticancer mechanisms of OSW-1 in cancer cells
References:
[1] Burgett AW, et al. Natural products reveal cancer cell dependence onoxysterol-binding proteins.Nat Chem Biol. 2011 Aug 7;7(9):639-47.
[2] Zhan Z, Liu Z, Lai J, Zhang C, Chen Y, Huang H. Anticancer Effects and Mechanisms of OSW-1 Isolated From Ornithogalum saundersiae: A Review. Front Oncol. 2021 Sep 23;11:747718.
[3] Ding X, Li Y, Li J, Yin Y. OSW-1 inhibits tumor growth and metastasis by NFATc2 on triple-negative breast cancer. Cancer Med. 2020 Aug;9(15):5558-5569.
[4] Zhang Y, Fang F, Fan K, Zhang Y, Zhang J, Guo H, et al. Effective Cytotoxic Activity of OSW-1 on Colon Cancer by Inducing Apoptosis In Vitro and In Vivo. Oncol Rep (2017) 37(6):3509–19.
[5] Yanhong,Zhang,Fengqi,et al.Effective cytotoxic activity of OSW-1 on colon cancer by inducing apoptosis in vitro and in vivo[J].Oncology Reports, 2017, 37(6).
OSW-1是一种发现虎眼万年青中的皂苷,抑制醇固醇结合蛋白(OSBP)及其类似物OSBP相关蛋白4(ORP4),并显示抗病毒和抗癌活性[1]。OSW-1已被证明通过抑制细胞增殖、阻止细胞周期、诱导细胞凋亡和高尔基应激反应,同时通过调节miRNAs表达和各种信号通路抑制迁移、侵袭和血管生成,从而抑制癌症进展[2]。
在体外实验中,在与OSW-1 100 ng/mL OSW-1共孵育24小时后,诱导的凋亡细胞(MDA-MB-231对MDA-MB-453细胞,52.5%对60.5%)比对照组更多。与对照组相比,OSW-1处理组的凋亡比率显著升高。在MDA-MB-231和MDA-MB-453细胞中,OSW-1组的凋亡细胞数量均高于对照组。与未经OSW-1处理的对照组相比,OSW-1处理组中蛋白水平的cleaved PARP和cleaved caspase 3的表达量增加了。此外,在100 ng/mL OSW-1处理的细胞中发现了过量表达的cleaved PARP和cleaved caspase 3,高于50 ng/mL OSW-1处理的细胞[3]。
在体内,处理组每日腹腔注射OSW-1(0.01 mg/kg,稀释于500 µl PBS),采用人裸鼠异位移植瘤模型,皮下接种LoVo细胞。与对照组相比,处理组观察到肿瘤大小和重量减少,且无明显副作用,Ki-67阳性细胞较少,凋亡细胞较多[4]。OSW-1处理的肿瘤组织中有大量凋亡细胞,而对照组凋亡细胞较少,表明OSW-1通过凋亡在体内抑制结肠肿瘤增殖。对照组小鼠肿瘤组织中存在多个坏死灶,而在OSW-1小鼠中不存在,证明对照组小鼠的肿瘤生长速度可能大于OSW-1处理小鼠[5]
Cell experiment [1]: |
|
Cell lines |
Human breast cancer cell lines |
Preparation method |
Human breast cancer (1×104 cells/well) were inoculated into 96-well plates and incubated overnight. Cells were treated with various concentrations of OSW-1(Orsaponin) (12.5, 25, 50, 100 ng/mL) for 24, 48 and 72 hours, then, the cytotoxicity was detected with cell count kit 8 (CCK8). |
Reaction Conditions |
12.5, 25, 50, 100 ng/mL |
Applications |
OSW-1(Orsaponin) doses varying from 12.5 to 100 ng/mL significantly reduced TNBC cell viability in a dose- and time-dependent manner. |
Animal experiment [2]: |
|
Animal models |
BALB/c-nu male mice (5–6 weeks of age, weighing 15–17 g) |
Preparation method |
Under sterile conditions, a 200-μL suspension (100 μL PBS and 100 μL Matrigel) of LN18 cells (1× 107 cells/mouse) was inoculated subcutaneously into the right armpit of nude mice. When the tumor volume reached 200 mm3, the mice were randomly divided into two groups with five mice in each group. The mice from the experimental and control groups were intraperitoneally injected with OSW-1 (0.01 mg/kg, diluted in 100 μL PBS) and the same volume of saline, respectively, every day for consecutive 21 days. |
Dosage form |
0.01 mg/kg |
Applications |
In OSW-1 treatment group, the tumors were evidently smaller, compared to the the control group; particularly, an evident reductionin the average tumor volume and weight was observed in the OSW-1 group. However, no signifcant diference was observed regarding the body weight between the two groups, indicating the low toxicity of OSW-1 in vivo. The western blotting assays of tumor tissue lysates showed that OSW-1 inhibited the expression levels of p-PI3K and p-Akt1 in the OSW-1 treatment group compared to the control group. Collectively, these results demonstrated OSW-1 inhibited glioma tumor progression by targeting PI3K/AkT signaling pathways in vivo. |
References: [1] Ding X, Li Y, Li J, Yin Y. OSW-1 inhibits tumor growth and metastasis by NFATc2 on triple-negative breast cancer. Cancer Med. 2020 Aug;9(15):5558-5569. [2] Zhan Z, Liu Z, Zhang C, Gao H, Lai J, Chen Y, Huang H. Anticancer effects of OSW-1 on glioma cells via regulation of the PI3K/AKT signal pathway: A network pharmacology approach and experimental validation in vitro and in vivo. Front Pharmacol. 2022 Sep 5;13:967141. |
Cas No. | 145075-81-6 | SDF | |
别名 | Orsaponin | ||
Canonical SMILES | O=C(CCC(C)C)[C@@H](C)[C@@]1(O)[C@@H](O[C@@H]2OC[C@H](O)[C@H](O[C@@H]3OC[C@@H](O)[C@H](O)[C@H]3OC(C4=CC=C(OC)C=C4)=O)[C@H]2OC(C)=O)C[C@@]5([H])[C@]6([H])CC=C7C[C@@H](O)CC[C@]7(C)[C@@]6([H])CC[C@@]51C | ||
分子式 | C47H68O15 | 分子量 | 873 |
溶解度 | Methanol: soluble | 储存条件 | Store at -20°C, protect from light, stored under nitrogen |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 1.1455 mL | 5.7274 mL | 11.4548 mL |
5 mM | 0.2291 mL | 1.1455 mL | 2.291 mL |
10 mM | 0.1145 mL | 0.5727 mL | 1.1455 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet